Unusual Volume Healthcare: Raptor Pharmaceutical (NASDAQ:RPTP), BioMarin Pharmaceutical (NASDAQ:BMRN), Synergy Pharmaceuticals (NASDAQ:SGYP), Onconova Therapeutics (NASDAQ:ONTX)

Raptor Pharmaceutical Corp. (NASDAQ:RPTP) has made an exciting and potential quality of life changing announcement today for people afflicted with the hereditary brain disorder Huntington’s disease. After the second phase of a three-phase trial of their experimental drug, RP103 (delayed-release cysteamine) the drug has been shown to be effective in slowing down the loss of muscle control and muscle spasms commonly experienced by people suffering from Huntington’s disease. Raptor Pharmaceutical Corp. (NASDAQ:RPTP) stock opened at $17.05 in last session, and closed at $17.14, while the day range of stock is $16.33 -$17.72. The stock showed a positive weekly performance of 10.65%.

BioMarin Pharmaceutical Inc.’s (NASDAQ:BMRN) Marketing Authorization Application for VIMIZIM for the treatment of Morquio A syndrome, also called Mucopolysaccharidosis Type IVA, has received a positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency. The European regulatory agency is expected to render its final decision for VIMIZIM in the second quarter of 2014. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) stock opened at $76.64, in last session and closed at $80.13, by gaining 4.95%. The 52 week range of the stock is $53.14 – $80.67. Company’s market capitalization is $11.40 billion.

Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal (GI), disorders and diseases. The Company’s lead product candidate is plecanatide, a guanylyl cyclase C (GC-C), receptor agonist, to treat GI disorders, primarily chronic constipation (CC), and constipation-predominant-irritable bowel syndrome (IBS-C). Synergy Pharmaceuticals Inc (NASDAQ:SGYP) stock advanced 8.86% and finished the last session at $5.90. The EPS of the stock remained -0.70. Company’s market capitalization is $532.07 million. Investment analysts at Leerink Swann reduced their price objective on shares of Onconova

Therapeutics (NASDAQ:ONTX) from $37.00 to $14.00 in a note issued to investors on Thursday, Stock Ratings Network.com reports. Leerink Swann’s price target indicates a potential upside of 59.27% from the stock’s previous close. Onconova Therapeutics Inc (NASDAQ:ONTX) stock opened the session at $8.28, and closed the session at $8.79. The 52 week range of the stock remained $7.75 – $31.13 and the day range was $7.75 – $8.87.